Shockwave Medical Inc (NASDAQ:SWAV) insider Isaac Zacharias sold 4,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $40.24, for a total transaction of $160,960.00. Following the completion of the transaction, the insider now directly owns 9,000 shares in the company, valued at approximately $362,160. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Isaac Zacharias also recently made the following trade(s):
- On Monday, November 11th, Isaac Zacharias sold 4,000 shares of Shockwave Medical stock. The stock was sold at an average price of $35.66, for a total transaction of $142,640.00.
- On Friday, October 11th, Isaac Zacharias sold 4,000 shares of Shockwave Medical stock. The stock was sold at an average price of $32.68, for a total transaction of $130,720.00.
Shares of NASDAQ SWAV traded down $0.11 during trading on Friday, hitting $43.88. 58,797 shares of the company were exchanged, compared to its average volume of 642,104. Shockwave Medical Inc has a 12-month low of $24.58 and a 12-month high of $68.39. The company has a quick ratio of 6.28, a current ratio of 6.76 and a debt-to-equity ratio of 0.09. The company has a fifty day moving average price of $36.92 and a 200-day moving average price of $42.99.
SWAV has been the topic of a number of recent research reports. ValuEngine downgraded shares of Shockwave Medical from a “buy” rating to a “hold” rating in a research note on Thursday, November 14th. Canaccord Genuity cut their price target on shares of Shockwave Medical from $65.00 to $49.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Oppenheimer assumed coverage on shares of Shockwave Medical in a report on Tuesday, October 22nd. They issued a “market perform” rating on the stock. Piper Jaffray Companies increased their target price on shares of Shockwave Medical from $43.00 to $46.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Wells Fargo & Co upgraded shares of Shockwave Medical from a “market perform” rating to an “overweight” rating and set a $49.00 price target on the stock in a report on Thursday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $44.00.
Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Shockwave Medical by 1,232.2% in the second quarter. Vanguard Group Inc. now owns 666,096 shares of the company’s stock worth $38,028,000 after acquiring an additional 616,096 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Shockwave Medical during the 2nd quarter valued at about $18,115,000. Gilder Gagnon Howe & Co. LLC raised its holdings in shares of Shockwave Medical by 15.9% during the 3rd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,676,916 shares of the company’s stock valued at $50,190,000 after buying an additional 229,515 shares during the period. Jennison Associates LLC acquired a new stake in Shockwave Medical during the 2nd quarter valued at approximately $11,323,000. Finally, Price T Rowe Associates Inc. MD grew its stake in Shockwave Medical by 8.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 2,057,775 shares of the company’s stock valued at $114,072,000 after purchasing an additional 162,999 shares in the last quarter. Institutional investors and hedge funds own 58.43% of the company’s stock.
Shockwave Medical Company Profile
ShockWave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease.
Featured Article: Percentage Gainers
Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.